real-time news and commentary for investors
Wednesday, Aug 15
2012, 7:10 PM
Medivation (MDVN) and and Japanese drug maker Astellas Pharma say results from its Phase 3...
Medivation (MDVN) and and Japanese drug maker Astellas Pharma say results from its Phase 3 Affirm trial of Enzalutamide have been published in the New England Journal of Medicine. The paper, "Increased Survival with Enzalutamide in Prostate Cancer After Chemotherapy," appears in the August 15 online issue. In the trial, the data showed that enzalutamide exhibited a statistically significant benefit in overall survival compared to a placebo.